91 related articles for article (PubMed ID: 2224945)
1. Choosing a target for cognitive enhancers.
Allain H; Bentué-Ferrer D; Decombe R
Clin Ther; 1990; 12(4):298-305; discussion 297. PubMed ID: 2224945
[TBL] [Abstract][Full Text] [Related]
2. Preclinical research into cognition enhancers.
Sarter M
Trends Pharmacol Sci; 2006 Nov; 27(11):602-8. PubMed ID: 16997388
[TBL] [Abstract][Full Text] [Related]
3. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
4. Alternative strategies in drug development: clinical pharmacological aspects.
Kuhlmann J
Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
[TBL] [Abstract][Full Text] [Related]
5. The development of behavioral tests to assess the effects of cognitive enhancers.
Olton DS; Wenk L
Pharmacopsychiatry; 1990 Feb; 23 Suppl 2():65-9. PubMed ID: 2186416
[TBL] [Abstract][Full Text] [Related]
6. [Hippocampus: a target for cognition enhancers].
Arushanian EB; Beĭer EV
Eksp Klin Farmakol; 2007; 70(4):59-65. PubMed ID: 18078044
[TBL] [Abstract][Full Text] [Related]
7. Cognitive endpoints as disease biomarkers: optimizing the congruency of preclinical models to the clinic.
Day M; Balci F; Wan HI; Fox GB; Rutkowski JL; Feuerstein G
Curr Opin Investig Drugs; 2008 Jul; 9(7):696-706. PubMed ID: 18600575
[TBL] [Abstract][Full Text] [Related]
8. Animal models of cognitive function.
Decker MW
Crit Rev Neurobiol; 1995; 9(4):321-43. PubMed ID: 8829849
[TBL] [Abstract][Full Text] [Related]
9. On the trail of a cognitive enhancer for the treatment of schizophrenia.
Stip E; Chouinard S; Boulay LJ
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):219-32. PubMed ID: 15694228
[TBL] [Abstract][Full Text] [Related]
10. Fish oil and mental health: the role of n-3 long-chain polyunsaturated fatty acids in cognitive development and neurological disorders.
Assisi A; Banzi R; Buonocore C; Capasso F; Di Muzio V; Michelacci F; Renzo D; Tafuri G; Trotta F; Vitocolonna M; Garattini S
Int Clin Psychopharmacol; 2006 Nov; 21(6):319-36. PubMed ID: 17012979
[TBL] [Abstract][Full Text] [Related]
11. [Nootropes (cognition enhancers) and neuroprotectors].
Vornin TA; Seredenin SB
Eksp Klin Farmakol; 2007; 70(4):44-58. PubMed ID: 18078043
[TBL] [Abstract][Full Text] [Related]
12. Developing drugs for cognitive impairment in schizophrenia.
Breier A
Schizophr Bull; 2005 Oct; 31(4):816-22. PubMed ID: 16150959
[TBL] [Abstract][Full Text] [Related]
13. Is it time to revisit the role of psychedelic drugs in enhancing human creativity?
Sessa B
J Psychopharmacol; 2008 Nov; 22(8):821-7. PubMed ID: 18562421
[TBL] [Abstract][Full Text] [Related]
14. Effects of valium and librium on human psychomotor and cognitive functions.
Murray JB
Genet Psychol Monogr; 1984 May; 109(2D Half):167-97. PubMed ID: 6329901
[TBL] [Abstract][Full Text] [Related]
15. Acetylcholinesterase inhibitors, neuropsychiatric symptoms, and Alzheimer's disease subtypes: an alternate hypothesis to global cognitive enhancement.
Brousseau G; Rourke BP; Burke B
Exp Clin Psychopharmacol; 2007 Dec; 15(6):546-54. PubMed ID: 18179307
[TBL] [Abstract][Full Text] [Related]
16. Testosterone replacement therapy for the treatment of neurological and neuropsychiatric disorders.
Gold SM; Voskuhl RR
Curr Opin Investig Drugs; 2006 Jul; 7(7):625-30. PubMed ID: 16869115
[TBL] [Abstract][Full Text] [Related]
17. The neurobiology of cognition in schizophrenia.
Tamminga CA
J Clin Psychiatry; 2006; 67 Suppl 9():9-13; discussion 36-42. PubMed ID: 16965183
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacologic treatment for cognitive disorders: an update].
Lestage P
Therapie; 2000; 55(4):507-12. PubMed ID: 11098728
[TBL] [Abstract][Full Text] [Related]
19. Developing predictive animal models and establishing a preclinical trials network for assessing treatment effects on cognition in schizophrenia.
Floresco SB; Geyer MA; Gold LH; Grace AA
Schizophr Bull; 2005 Oct; 31(4):888-94. PubMed ID: 16079387
[TBL] [Abstract][Full Text] [Related]
20. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.
Nuechterlein KH; Green MF; Kern RS; Baade LE; Barch DM; Cohen JD; Essock S; Fenton WS; Frese FJ; Gold JM; Goldberg T; Heaton RK; Keefe RS; Kraemer H; Mesholam-Gately R; Seidman LJ; Stover E; Weinberger DR; Young AS; Zalcman S; Marder SR
Am J Psychiatry; 2008 Feb; 165(2):203-13. PubMed ID: 18172019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
